Trial Profile
89Zr-pembrolizumab-PET Imaging in Patients With Locally Advanced or Metastatic Melanoma or Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Nov 2021
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer
- Focus Diagnostic use
- 01 Nov 2021 Results published in the Annals of Oncology
- 03 Sep 2020 Status changed from active, no longer recruiting to completed.
- 01 Oct 2019 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.